Asociación de ciclofosfamida a nanoesferas de polibutil-cianoacrilato

Ciencia y Tecnologia Pharmaceutica

Volumn 10, Issue 1, 2000, Pages 14-19

  Salgueiro, M A ^a   Garcia M I ^a   Espina, M ^a   Valls, O ^a   Egea, M A ^a  

^a NONE

Author keywords

Alkylcyanoacrylate; Central composed design; Nanospheres; Release controled systems

Indexed keywords

ALKYLCYANOACRYLIC ACID; CYCLOPHOSPHAMIDE; DRUG CARRIER; NANOPARTICLE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CONTROLLED DRUG RELEASE; DRUG DESIGN; DRUG DETERMINATION;

EID: 0034072872     PISSN: 11315253     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Boughton OD, Brown RD, Bryant R, Burger FJ, Combs CM: Assay of ciclophosphamide. J Pharm Sci, 1972; 61(1):97-100
2. a Ed. Little Brown & Co. Boston, 1987.
3. Garrity JA, Kennerdell JS, Johnson BL, Ellis LD: Cyclophosphamide in the treatment of orbital vasculitis. American Journal of Ophthalmology, 1986; 102:97-103.
4. Couvreur P, Kante B, Roland M, Guiot P, Baudin P, Speiser P: Polyalkylcyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol, 1979; 31:331-332.
5. McConnell ML: Particle size determination by quasielastic Light Scattering. Anal Chem, 1981; 53:1007A-1018A.
6. Salgueiro A, Egea MA, Vallls R, Espina M, Garcia ML: An inductively coupled plasma method for determination of cyclophosphamide loaded to polymeric systems. J Pharm Biomed Analysis, 1999; 21:611-618.
7. Carpignano R, Gasco MR, Morel S: Optimization of doxorubicine incorporation and of the yield of polybutylcyanoacrylate nanoparticles. Pharm Acta Helv, 1991; 66:28-32.
8. Egea MA, Gamisans F, Valero J, Espina M, García ML: Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles. II Farmaco, 1994; 49(3):211-217.
9. Schoenwald RD, Stewart P: Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci, 1980; 69:391-394.